Aptose Biosciences (APS) AI Stock Analysis

• Market Cap: $8.37M
• Dividend Yield: N/A
• Average Volume (3M): 5.57K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.37
• Revenue Growth: N/A
• EPS Growth: 79.63%
• Country: CA
• Employees: 35
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): -63.90
• Shares Outstanding: 2,552,429
• 10 Day Avg. Volume: 3,964
• 30 Day Avg. Volume: 5,574
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.79
• Price Target Upside: 289.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Aptose Biosciences' financial struggles are significant, with no revenue and considerable losses weighing heavily on its overall score. However, positive corporate developments in AML therapy offer some hope for future growth and funding. Technical indicators suggest a bearish market sentiment, while valuation metrics reflect ongoing challenges with profitability.

Positive Factors

Clinical Development

Aptose, along with Hanmi Pharmaceutical, is negotiating a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development.

Clinical Trial Outcomes

TUSCANY exhibits initial signs of promise in newly diagnosed AML, with preliminary safety and efficacy data showing positive results.

Financial Stability

The company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.

Negative Factors

Clinical Trial Risks

The company must continue to manage and monitor the TUSCANY trial to ensure the absence of safety signals and maintain favorable safety and tolerability.

Funding Requirements

Aptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement designed to provide necessary additional funding and accelerate clinical development.

Aptose Biosciences Business Overview & Revenue Model

Company Description

Aptose Biosciences Inc. (APS) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of highly differentiated therapeutics addressing unmet medical needs in oncology. The company specializes in developing targeted therapies for the treatment of hematologic malignancies and other life-threatening diseases. Aptose leverages a deep understanding of cancer biology to develop innovative small molecule cancer drugs.

How the Company Makes Money

Aptose Biosciences generates revenue primarily through the development and potential commercialization of its proprietary drug candidates. The company seeks to monetize its innovations through strategic partnerships with larger pharmaceutical companies, licensing agreements, and eventual sales of approved therapeutics. Revenue streams may include upfront payments, milestone payments, royalties on product sales, and research and development funding from partners. As a clinical-stage company, Aptose's financial performance heavily depends on the successful clinical development, regulatory approval, and commercialization of its drug candidates.

Aptose Biosciences Financial Statement Overview

Summary

Aptose Biosciences exhibits financial instability typical for early-stage biotech firms, with no revenue generation, negative equity, and reliance on external financing. The ongoing operational challenges and lack of revenue present significant risks.

Income Statement

Aptose Biosciences has not generated any revenue over the analyzed periods, resulting in consistently negative profits. The net profit margin, EBIT, and EBITDA margins are all significantly negative, reflecting ongoing operational challenges and lack of revenue generation typical in early-stage biotech companies focused on development.

Balance Sheet

The company's balance sheet shows high leverage with negative stockholders' equity in the latest TTM, indicating financial instability. The debt-to-equity ratio is not meaningful due to negative equity. This poses significant risk, although earlier periods showed stronger equity positions.

Cash Flow

Cash flow analysis reveals consistently negative operating and free cash flows, with a significant discrepancy between operating cash flow and net income. The company relies heavily on financing activities to sustain operations, which is a typical but risky strategy in pre-revenue biotech companies.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00	0.00
	EBIT
-36.20M	-52.36M	-42.59M	-65.45M	-55.78M	-26.86M
	EBITDA
-35.78M	-52.27M	-42.06M	-64.82M	-55.16M	-26.25M
	Net Income Common Stockholders
-35.80M	-51.21M	-41.05M	-65.26M	-54.71M	-25.70M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.08M	9.25M	46.96M	79.13M	122.39M	97.60M
	Total Assets
2.46M	12.99M	51.03M	82.53M	126.26M	100.48M
	Total Debt
0.00	1.01M	1.30M	574.00K	1.07M	1.53M
	Net Debt
-844.83K	-8.24M	-35.67M	-38.54M	-116.32M	-78.31M
	Total Liabilities
1.36M	15.89M	13.29M	8.29M	7.35M	6.55M
	Stockholders Equity
1.10M	-2.90M	37.74M	74.24M	118.92M	93.93M
Cash Flow		Free Cash Flow
-37.18M	-44.62M	-32.35M	-43.52M	-33.97M	-21.66M
	Operating Cash Flow
-37.18M	-44.59M	-32.32M	-43.30M	-33.89M	-21.56M
	Investing Cash Flow
1.96M	9.96M	30.07M	-35.21M	12.63M	-17.37M
	Financing Cash Flow
27.46M	6.91M	116.00K	226.00K	58.81M	103.45M

Aptose Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APS, the sentiment is Neutral. The current price of 3.28 is below the 20-day moving average (MA) of 3.54, below the 50-day MA of 4.83, and below the 200-day MA of 12.35, indicating a bearish trend. The MACD of -0.54 indicates Negative momentum. The RSI at 42.98 is Neutral, neither overbought nor oversold. The STOCH value of 52.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:APS.

Aptose Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GUD	65 Neutral	$568.85M	131.14	0.53%	―	13.13%	―
QNC	51 Neutral	$108.86M	―	-669.49%	―	―	―
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
ONC	42 Neutral	$72.59M	―	-184.69%	―	―	0.10%
CRDL	34 Underperform	$108.22M	―	-138.82%	―	―	-18.03%
APS	32 Underperform	$8.37M	―	391.94%	―	―	79.63%

Aptose Biosciences Corporate Events

Aptose Biosciences Advances AML Therapy and Strengthens Financial Position

Aptose Biosciences has reported its year-end 2024 results and highlighted significant advancements in its tuspetinib-based triple drug therapy for AML. The ongoing TUSCANY clinical trial has shown promising results, achieving complete remissions in difficult-to-treat AML patients. The company has also signed a debt conversion agreement with Hanmi Pharmaceutical and entered a cooperative research agreement with the National Cancer Institute to further develop tuspetinib. These developments are expected to enhance Aptose’s position in the oncology market and provide additional funding for its clinical programs.

Promising Early Results from Aptose’s TUSCANY Trial in AML Treatment

Aptose Biosciences has reported promising early results from their TUSCANY trial, involving the TUS+VEN+AZA triplet therapy for newly diagnosed AML patients. The trial, which uses a combination of tuspetinib, venetoclax, and azacitidine, has shown complete remissions in patients with TP53-mutated and FLT3-wildtype AML, demonstrating favorable safety and efficacy. These results indicate a potential new frontline treatment for a diverse group of AML patients, enhancing Aptose’s position in the oncology field and offering hope for stakeholders.